Intravitreal Ranibizumab in the Treatment of Predominantly Hemorrhagic Lesions in Exudative Age-Related Macular Degeneration.

Détails

ID Serval
serval:BIB_19C80A4FB918
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Intravitreal Ranibizumab in the Treatment of Predominantly Hemorrhagic Lesions in Exudative Age-Related Macular Degeneration.
Périodique
Klinische Monatsblatter Fur Augenheilkunde
Auteur(s)
Konstantinidis L., Mantel I., Zografos L., Ambresin A.
ISSN
1439-3999 (Electronic)
ISSN-L
0023-2165
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
228
Numéro
4
Pages
288-292
Langue
anglais
Notes
Publication types: JOURNAL ARTICLEPublication Status: ppublish
Résumé
BACKGROUND: Submacular hemorrhage is a manifestation of neovascular age-related macular degeneration (AMD) that has a very poor natural history leading to severe visual loss. We have evaluated the safety and efficacy of intravitreal ranibizumab in the treatment of predominantly hemorrhagic AMD. PATIENTS AND METHODS: A retrospective study of patients with predominantly hemorrhagic AMD treated with intravitreal ranibizumab at the Jules Gonin Eye Hospital between December 2006 and December 2008 was undertaken. Baseline and monthly follow-up exams included visual acuity (VA), fundus exam and optical coherence tomography (OCT) while fluorescein and indocyanine green angiography were performed at least every three months. RESULTS: The study included 8 eyes. The mean follow-up was 13 months (SD: 6.3). The mean number of intravitreal injections administered for each patient was 6.4 (SD: 2). 50 % of the patients demonstrated stable or improved VA. The size of hemorrhage at baseline was inversely correlated to the final VA (two-tailed p value = 0.038) and positively correlated to the final central macular thickness (two-tailed p value = 0.021). Anticoagulation treatment was inversely correlated to the time of hemorrhage resolution (two-tailed p value = 0.039). CONCLUSIONS: Intravitreal ranibizumab may be an effective treatment for predominantly hemorrhagic lesions due to neovascular AMD.
Pubmed
Web of science
Création de la notice
18/04/2011 18:38
Dernière modification de la notice
20/08/2019 12:50
Données d'usage